it's hard to believe that 10 years ago Amazon introduced the fir phone which was a complete flop and it lost a ton of money but since then Amazon's stock has gone up over 1,200% in the past 10 years so that $10,000 invested with Amazon in 2014 would be over $120,000 today but if a person used the rule of 40 to decide if they should invest in Amazon back then it would have told you not to invest and as a refresher the ru of 40 states that for software companies if you add up their revenue growth
and their profit margins and if it's equal to or greater than 40% then it's a healthy company to invest in but in 2014 Amazon's revenue growth was at 20% and their margin was only at a netive 0.27% the rule of 40 would have guided you not to invest in Amazon and that's the flaw with rules like this when companies are in their startup mode or they're just about to explode in growth that's why I'm going to cover my top five stocks to 10x within 10 years where I try to balance out the financials along with
the art of choosing companies that are going to fulfill a customer need that may not even exist yet and I'll give you my disclaimer right from the beginning that I may be wrong on 70% of these but I'm only banking on having a couple of them right now I'm making this video because it was requested after I had reviewed the top analyst picks that were going to make us all millionaires where I dissected those companies apart using mostly common sense and the link is right up here if you want to check that video out and
true to form I'm not going to keep keep the list a secret you can always ditch the video right after I give my list but the real value is seeing why I picked them in the first place my list of 10 begger hopefuls is d-wave Summit Therapeutics Archer Joby Viking Therapeutics and paler and I'm also going to throw in a bonus one which is a company that's going to have its IPO in the next 2 to 3 months and is one of the few IPOs that I'm actually excited about so there it is that's my
list that's all you want it's not going to hurt my feelings if you completely ditch the video and if you also don't want to give me a like or a subscribe but if you do stick around I think it's truly worth hearing why they made my list similar to my prior video on 10 Beggars I'll rate them from 1 through 10 with 10 being the best score for the three areas of market cap fundamentals and the future potential and I'm the first to admit that there is a lot of subjectivity that's baked in so feel
free to share your opinions if you believe that I've missed something the first company I'll speak to is d-wave quantum with the symbol qbts referencing cubits which develops and delivers Quantum Computing systems software and services worldwide the company's Quantum Solutions are used in scheduling Mobility Logistics drug Discovery portfolio optimization and Manufacturing processes where they recently unveiled a 4400 Cubit advantage to processor the touts having a 40% boost in energy scale and doubling its coherence time and this is several times larger in cubits than any other quantum computer right now and I'm not going to get
too technical but quantum computers are able to process enormous amounts of data and models that are hundreds of years quicker than traditional computers granted they won't replace traditional computers which means that this technology well it's only going to be a creative to all other technological advancements and when we look at the performance it's up over 63% year-to date but bringing us down a notch it is down 88% from its IPO in 20120 so be thankful I hope that you didn't invest in it 4 years ago but in using some common sense I love that the
market cap is only at $290 million which means that if this company grows 10 times or 10 x's in 10 years then the market cap would be 2.9 billion which is extremely realistic but when we look at the financials it's obvious that this is a startup and the fundamentals tell me this is not a stock to invest a whole lot into they are burning through cash and their debt to assets is very high the only upside is that they have several beats to the estimates in the lower right quadrant and analysts are giving d-wave some
love with a 53% upside for the forecasted next 12 months and here's my rating for d-wave under my three main criteria so for fundamentals I only give them a one market cap they at the top with a 10 and future potential is also a 10 giving it a total score of 20 just kidding it's it's a 21 but I'll probably say one of them wrong just to see how many people are going to comment on it overall the stock is touching on future technology that isn't widely adopted or available to most of us us but
it is priced low enough right now that I'm willing to invest a few thousand into it and just write it out for the next decade the next company to review is Summit Therapeutics which is a biopharmaceutical company that's on the radar for their Cancer drugs that are tackling non small cell lung cancer with their drug well I'm going to put it on the screen because I really don't want to murder it by how I would pronounce it wrong but the drug is different from others because well first off it blocks pd1 which enhances the immune
system in order to fight off cancer cells and second it inhibits vegf which helps prevent the formation of new blood vessels that happen to be feeding the tumors in essence it comes with a onew punch that other drugs like Kuda just don't offer the drug is on a fast track with the FDA so approval might be 1 to two years out it has shown a high efficacy by reducing progression and death by 49% compared to the competitor's drug in looking at the performance year-to date it's kind of ridiculous up 72% but it does have room
to grow the market cap is at 16 billion so it is within our window of opportunity unfortunately this is a purely speculative stock because yes they do have product in Trials but they don't have anything today that's driving Revenue in sales so it is totally in its design and building stages everything is banking on FDA approval but since they received a FasTrack in my mind that's encouraging because when we look at Revenue it is a big hole and the debt to assets is increasing at a slower rate and investors are its only form of cash
flow but they are managing cost well which is showing in the earnings per share which is negative but it does show that they are managing their business within a smart window of expectations and the analysts are giving Summit 58% goodness in their projections for the next year in Breaking the stock down under my criteria for Summit I give it a one for fundamentals because well they are managing their costs but they aren't selling anything yet and I give the market cap a 10 because if it were to 10x in 10 years that would put it
at $160 billion which is realistic considering the competitors drug Kuda is generating $25 billion a year and since they had Stellar results in Trials I'm giving the future potential a nine I would have given it a 10 but everything hinges on that FDA approval this company has great upside but without having a physical product generating income today then it's difficult to want to invest a ton of money right away so it's a good one to cost value average in my opinion another way that I like to diversify and try to 10x my investments is by
owning my own business then there is an option that pays 7 to 9% a month on invested Capital that's where today's sponsor limits Express comes into play they work as business managers to create and manage an Amazon store just for you where they buy and sell National branded products using your capital and business they do all the heavy lifting and all of the day-to-day work they don't get paid unless your Amazon business makes a profit in full transparency I have invested with limits Express to vet them out and to verify their process my first two
full months of sales came in at just over $112,000 with nearly a $1,200 profit so that's a margin of 9% I admit that the process starts off a little bit slow because you need to get approvals to sell the brands but that's due to Amazon and its processes so if you're interested in learning more I'll have a link down in the description so that you can speak directly with Kyle which happens to be one of the co-founders you can also check out their website down in the links below and please keep in mind that all
Investments carry some level of risk and this is not a personal recommendation now we'll get into one of my favorite companies paler where they are a software company with a truly unique AI model built from the ground up and I truly hope that you saw my videos last year where I was trying to get the gospel out that paler has an incredible product and their profits and their demand well they're going to Skyrocket with their shift to more of a commercial customer truly they have the most Innovative AI product that I've ever seen where it
automates and it improves a company's entire Enterprise software solution in fact in a recent cas study Wendy's partnered with paler when they used it to leverage for their supply chain and for forecasting features where they instantly saw a competitive Advantage from the software and they've already stated that the ROI has been significant now when we look at the performance it is up over 21% year-to date and I fully expected to still have many dips here and there where we'll all get the chance to buy more because when we look at the PE Ratio it is
an insane 256 so it's pretty obvious that there is a lot of expectations baked into the price and the financials begin to tell us why the expectation is so high the revenue earnings and the profit margin have all been on a constant climb and that's the message I was showing last year when I was trying to share the fact that once they break over into positive earnings the stock is going to take off which it did and then there's the debt to assets where it has dropped off a cliff which is completely awesome to see
and the cash flow picture looks steady except for the investing and then there's the beat to forecasted earnings per share consistently each quarter on the lower right side and when you bring this all together it's no surprise that this has been a Cinderella story all year analysts aren't seeing upside for paler seeing as how they have them down 43% for the next 12 months however I have a very strong feeling that analysts will be changing their forecast over the next couple months giving paler a little bit more goodness than what you see right here and
once again just my opinion so when I break down paler score for fundamentals I'm giving them a solid 10 because they're hitting on all cylinders and for market cap I'm going to them and only shell out an eight because to 10x in 10 years they'd be about a $1.4 trillion company and don't get me wrong it's completely doable but that's assuming that their demand will keep increasing at this current Pace or more and when it comes to Future potential pener doesn't really have any competition that comes anywhere close to the complex level of its systems
that they offer today once they can push ahead with marketing and distribution then they can blow up even faster and I love the fact that they're showcasing their wins on the commercial side and not just their government cont contracts I had already come to the conclusion about a year ago that paler was going to be part of my Elite 8 Investments and you can easily see that when you look at my portfolio that I share in my newsletter before moving on to the next company I do want to mention a bonus company that I am
actually excited about with their upcoming IPO and that would be cerebus which is a semiconductor company that is in huge demand because they're creating their wafer scale Engine with four trillion transistors and over 900,000 AI optimized cores they have a lot of customers but so much of the information on the company happens to be private so there isn't a lot of information that we have access to however the word on the street is that they plan to go public in the next 2 months and I simply want to get it out on your radar and
I have to admit that I often don't like IPOs and this one is also going to depend on how the valuation goes but overall I see this one is a ton of potential so I'm just throwing it out there so you know it exists the next company is Viking Therapeutics which is a biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders they have a glp1 drug in trials for an oral pill form that will greatly expand the weight loss drug offering and also they have one in the form of injections like those that
are already on the market in addition to these they're also completing trials for thyroid metabolic disorders for more diversity within their product offering Viking does have a lot of momentum so far at over 240% return year-to date and they are up over 1,000% in the past 3 years their market cap is $7 billion so that's definitely within our window and they don't have have a PE because well they don't have any product on the market yeah this is another one of those speculative stocks where they do have a product within trials but they don't have
any products launched to actually generate Revenue that's why when we look at the financials the earnings are negative leading up to the launching of the product but thankfully this is another case where the company is managing their debt to assets quite well in the upper right and their cash flow well that really doesn't tell me much but their earnings per share are beating expectations because they happen to be managing their expenses as well I'll quickly point out that analysts have Viking with a 12-month forecast of a 79% upside so in breaking down Viking Therapeutics I
give them a two for fundamentals because they are still in that speculative startup mode until they have FDA approvals as for market cap I give them a 10 because they have a long Runway given the breadth of drugs that they have in the pipeline and for potential I give them a solid nine I'd love to give them a 10 but the reality is there is a lot of competition in this space and the next company is Archer Aviation but quite honestly you could probably choose either Joby or Archer and I feel that they're both going
to be very similar in standings but for me I lean a little bit more towards Archer where they design and build electric vertical takeoff and Landing aircraft meant for urban Mobility or relatively short distances between 20 to 50 Mi mil and they have a 400,000 ft production facility in Georgia that's going live in the next month or so and they plan to produce two aircraft a month in 2025 but they will have capacity to make 650 aircraft a year once they're at full capacity and the next major hurdle is in the FAA certifications which they
hope to complete the fourth phase next year with the potential of having commercial flights by the end of 2025 now I've spoken about Archer a few times in the past and a lot of people have pushed back on the battery limitations and also safety and I believe those are fair concerns but batteries aren't going to stop it from making short flights that it's intended for and as for safety these EV talls have more safety redundancies than you see from any helicopter out in the market but since it is is not in full production and it
hasn't even completed all of its FAA certifications we don't really know all the details on safety or what to expect and I have to say it's not a Rosy picture when we look at the performance year-to date at a netive 26% but the momentum is truly going to kick in between now and when they start commercial flights in 12 to 18 months I can genuinely see this as a company where people will be kicking themselves for not buying it when it was just $3 a few weeks ago but for the extremely logical person out there
when you look at the financial where they're still ramping up the business without having any positive Revenue it's not a stock that you want to get too excited over and the debt to assets is growing quickly as they prepare for production and I can't read much from the cash flow since it's all investor Capital but the beating of earnings per share to forecast well it's pretty good because they are ahead of expectations and the way that analysts are viewing Archer they have them with 119% upside for the next 12 months so how exactly am I
going to boil this down for Archer well for fundamentals I give them a one because it's a high capex company that's still waiting on FAA approvals and for market cap I give them a 10 since they're only at 1.6 billion today and to reach 16 billion in 10 years honestly I think that's extremely achievable and as for potential I give them a solid 10 because it's at the very beginning of the race and there's only a few companies like Joby and xang that are in the running so when we compare all of these companies at
once on the screen they would rank from top to bottom to 10x in 10 years based on my subjective scoring it would be paler with a 20 8 Archer 21 Viking 21 d-wave 21 and Summit comes in last out of 20 I'm guessing that there are several of you out there that are going to disagree with my selection or even my scoring and that's okay feel free to drop your thoughts and your ideas down in the comments so that others can hear what you think and point out anything I may have missed and I know
that many of you don't like the risk that's associated with individual stocks so I highly recommend that you check out one of my other videos on high growth ETFs thanks so much for watching
